Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL
Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL (  )
3 Jun 2022
COMy 2022: Multiple myeloma roundup
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
24 May 2022
Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients
Prof Natacha Bolaños - Lymphoma Coalition, Madrid, Spain
Lymphoma Coalition: Challenges for Ukrainian haematological cancer patients ( Prof Natacha Bolaños - Lymphoma Coalition, Madrid, Spain )
28 Apr 2022
Natural killer cells complexed with a bispecific antibody may provide new treatm...
Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, US...
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma ( Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Apr 2022
Minimal residual disease in multiple myeloma
Prof Ola Landgren - University of Miami, Miami, USA
Minimal residual disease in multiple myeloma ( Prof Ola Landgren - University of Miami, Miami, USA )
8 Mar 2022
Real-world evidence on PET use in Hodgkin lymphoma: An Argentinian perspective
Dr Marta Zerga - Hospital Alemán , Buenos Aires, Argentina
Real-world evidence on PET use in Hodgkin lymphoma: An Argentinian perspective ( Dr Marta Zerga - Hospital Alemán , Buenos Aires, Argentina )
3 Mar 2022
Cancer nursing in India: Tumour lysis syndrome
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Cancer nursing in India: Tumour lysis syndrome ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
28 Feb 2022
Cancer nursing in India: Febrile neutropenia
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Cancer nursing in India: Febrile neutropenia ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
28 Feb 2022
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL
Dr Juliana Pereira & Dr Steven Horwitz
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL ( Dr Juliana Pereira & Dr Steven Horwitz )
22 Feb 2022